ACE2 and asthma: A study also suggested that ICS therapy can reduce ACE-2 and transmembrane protease serine 2 enzyme (TMPRSS2) gene expression from sputum [79], which may protect against COVID-19 alongside providing therapeutic benefits for asthma.